Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Total Liabilities (2021 - 2025)

Zymeworks' Total Liabilities history spans 5 years, with the latest figure at $78.0 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 37.24% to $78.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.0 million, a 37.24% decrease, with the full-year FY2025 number at $78.0 million, down 37.24% from a year prior.
  • Total Liabilities hit $78.0 million in Q4 2025 for Zymeworks, up from $77.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for ZYME hit a ceiling of $155.8 million in Q4 2022 and a floor of -$282.4 million in Q1 2022.
  • Historically, Total Liabilities has averaged $53.4 million across 5 years, with a median of $115.9 million in 2023.
  • Biggest five-year swings in Total Liabilities: surged 168.89% in 2023 and later tumbled 37.24% in 2025.
  • Tracing ZYME's Total Liabilities over 5 years: stood at $140.0 million in 2021, then increased by 11.23% to $155.8 million in 2022, then dropped by 25.48% to $116.1 million in 2023, then increased by 7.11% to $124.3 million in 2024, then tumbled by 37.24% to $78.0 million in 2025.
  • Business Quant data shows Total Liabilities for ZYME at $78.0 million in Q4 2025, $77.2 million in Q3 2025, and $73.9 million in Q2 2025.